We will update these measurements every 3 months throughout your treatment to track your progress
ABSTRACT INTRODUCTION GLUCAGON GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE GLUCAGON-LIKE PEPTIDE-1 DUAL GLUCAGON/GLUCAGON-LIKE PEPTIDE-1 RECEPTOR CO-AGONISTS DUAL GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE/GLUCAGON-LIKE PEPTIDE-1 RECEPTOR CO-AGONISTS TRIPLE GLUCAGON-LIKE PEPTIDE-1/GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE/GLUCAGON RECEPTOR TRIAGONISTS CONCLUSIONS Article information References ABSTRACT Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide
A perspective published in the Journal of Clinical Endocrinology and Metabolism titled "Approach to the Patient With Thyroid Nodules: Considering GLP-1 Receptor Agonists" concluded that GLP-1 receptor agonist therapy should not be withheld from patients with benign thyroid nodules
Lifestyle choices beyond medicationsleep quality, exercise intensity, protein intake, and stress managementaccount for 4060% of weight loss variation between patients taking identical doses
Exogenous GLP-1 improves gastric compliance in a dose-dependent manner (Schirra et al., 2002), reduces the frequency and amplitude of gastric antrum and duodenum contraction, inhibits the contractile force of gastric antrum and duodenum, increases pyloric tension, and stimulates pyloric tetanic and phase motion (Schirra et al., 2000)
